GINS1 encodes a subunit of the GINS complex, which is essential for DNA replication initiation and replication fork progression. GINS1 is a core component of the CDC45-MCM-GINS (CMG) helicase complex, the molecular machine responsible for unwinding template DNA during replication and around which the replisome is assembled. In cancer contexts, GINS1 is significantly upregulated and serves as a prognostic biomarker. High GINS1 expression correlates with poor overall survival in liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and kidney renal clear cell carcinoma (KIRC) 1. In hepatocellular carcinoma, GINS1 promotes epithelial-mesenchymal transition and tumor metastasis through β-catenin signaling 2, while in lung adenocarcinoma it facilitates progression via Wnt/β-catenin pathway activation 3. In diffuse large B-cell lymphoma (DLBCL), the FOXP1-GINS1 axis drives proliferation and doxorubicin resistance 4, and PAX5-mediated GINS1 upregulation promotes B-cell proliferation and lymphoma progression 5. GINS1 expression is also correlated with methylation and immune escape in hepatocellular carcinoma 6. Therapeutically, GINS1 represents a potential target in multiple cancer types, with targeting the FOXP1-GINS1 axis proposed as a therapeutic approach for DLBCL treatment.